PT UBC Medical Indonesia Tbk
IDX:LABS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (25.8), the stock would be worth Rp148.1 (6% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 27.4 | Rp157 |
0%
|
| 3-Year Average | 25.8 | Rp148.1 |
-6%
|
| 5-Year Average | 25.8 | Rp148.1 |
-6%
|
| Industry Average | 15.9 | Rp91.28 |
-42%
|
| Country Average | 6.3 | Rp35.94 |
-77%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| ID |
P
|
PT UBC Medical Indonesia Tbk
IDX:LABS
|
620.2B IDR | 27.4 | 45.9 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
102.8B USD | 10 | 23.7 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
62.9B USD | 16 | 38.7 | |
| US |
|
Cencora Inc
NYSE:COR
|
60.6B USD | 15.5 | 37.3 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
48.3B USD | 8.8 | 29.1 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
32.3B AUD | 56.8 | 35.5 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
62.9B CNY | 12.2 | 11 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
9.1B USD | 16.8 | 22.8 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
59.9B CNY | 15 | 16.2 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | -316.6 | 89.6 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
61.9B HKD | 0.6 | 7.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 3.6 |
| Median | 6.3 |
| 70th Percentile | 14.1 |
| Max | 1 136 900.3 |
Other Multiples
PT UBC Medical Indonesia Tbk
Glance View
PT UBC Medical Indonesia Tbk is a ID-based company operating in Health Care Providers & Services industry. The company is headquartered in Jakarta Timur, Dki Jakarta and currently employs 64 full-time employees. The company went IPO on 2024-07-10. PT UBC Medical Indonesia Tbk is an Indonesia-based medical diagnostic company. The firm provides affordable medical diagnostic tests and instruments for the Indonesian healthcare market. The firm operates through two segments: Medical disposable and consumables, and Diagnostic and equipment. The company offers various products to detect and diagnose various diseases, such as tuberculosis, cervical cancer, newborn screening, COVID-19, health risk screening with artificial intelligence (AI) and molecular systems. Its products include NeoMoDX Molecular System, Airdoc, QIAstat-DX Analyzer, Care HPV System, Hybrid Capture 2 - HPV DNA Test, Revvity SARS-COV-2 RT PCR, Geneproof SARS-COV-2 PCR KIT, Quantiferon TB Gold Plus, Genoscholar, Ina TB, GSP Neonatal Kit, Delfia Neonatal Kit, Neonatal Sampling Paper and Victor2 D.
